Hypertension has been defined as resistant to treatment when a therapeutic plan that has included attention to lifestyle measures and the prescription of at least three antihypertensive drugs in adequate doses has failed to lower systolic (SBP) and diastolic (DBP) blood pressure (BP) sufficiently. 1,2 Subjects with resistant hypertension are at a greater risk for stroke, renal insufficiency, and cardiovascular events than individuals for whom BP is well controlled by medical therapy. 3 It has also been reported that many subjects, including those receiving antihypertensive therapy, show a "white-coat effect" that could cause an overestimation of their real BP. 4, 5 The impact of this effect on the occurrence of resistant hypertension seems to be highly variable among different studies, ranging from 20% up to 43% of the patients. 6,7 The prevalence of white-coat or isolated office resistant hypertension has been mainly estimated by comparing clinic BP with either home BP or the daytime BP values obtained from ambulatory BP monitoring (ABPM). Recent guidelines, 1 however, recommend the use of separate reference thresholds for night-time and daytime BP to define hypertension. In keeping with this recommendation, ABPM is the only valid method to differentiate "isolated office resistant hypertension" from "true resistant hypertension". 5-7 ABPM has the added advantage to provide higher prognostic value than office BP measurements in the evaluation of subjects with resistant hypertension. 8 In resistant hypertension, poor BP control may engender target organ damage and this, in turn, may become a cause of resistance to treatment. 4 Accordingly, there is 
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Background
Subjects with resistant hypertension present high prevalence of a nondipper blood pressure (Bp) pattern, associated with increased risk of cardiovascular events. Nondipping is partly related to the absence of 24-h therapeutic coverage in hypertensives treated with single morning doses.
Methods
We studied the impact of treatment time on ambulatory Bp and clinical characteristics of 1,794 subjects with resistant hypertension, categorized according to the time of treatment (either ingesting all antihypertensive medications upon awakening, or ≥1 drug at bedtime). Bp was measured for 48 consecutive hours, and physical activity was simultaneously monitored every minute by wrist actigraphy.
results
The percentage of controlled subjects was higher among those taking medication at bedtime (P < 0.001). Among the 1,306 participants with true resistant hypertension, those ingesting ≥1 drug at bedtime showed significantly lower 24-h mean of systolic Bp (SBp)/diastolic Bp (DBp) (by 4.1/1.5 mm Hg, respectively; P < 0.015). The difference between groups was more prominent in asleep Bp (9.7/4.4 mm Hg, P < 0.001). The awake/asleep Bp ratio was significantly higher by 5.8% (P < 0.001) and the prevalence of nondipping lower from 83 to 40% (P < 0.001) in subjects receiving bedtime treatment. This latter group also showed significant lower mean values of glucose, total cholesterol, low-density lipoproteincholesterol, fibrinogen, and urinary albumin excretion.
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increasing interest on how to treat individuals with resistant hypertension. Therapeutic strategies in resistant hypertension currently include adding another drug or changing one drug for a different one in search for a potentially better synergic combination. 1, 2 It has been reported that as much as 89% of treated hypertensive subjects, including those with resistant hypertension, ingest all their antihypertensive medication in the morning. 7, 9, 10 A recent prospective controlled trial documented that, in resistant hypertension, ingesting one antihypertensive drug at bedtime, as compared to treatment with all medication ingested upon awakening, was associated with a 40% increased BP control, a significant reduction of nighttime BP, and the corresponding remodeling of the BP pattern toward a more dipping profile. 11 This cross-sectional study extends previous findings 12 by investigating the impact of time of day of treatment on the circadian BP pattern, the degree of BP control, and relevant clinical and analytical parameters, in subjects with true resistant hypertension who were evaluated by 48-h ABPM in order to increase reproducibility of the results.
Methods
Inclusion and exclusion criteria. Inclusion criteria were age ≥18 years, and a diagnosis of resistant hypertension based on antihypertensive treatment for at least 3 months previous to evaluation by ABPM with a stable scheme consisting of ≥3 BP-lowering medications, in an adequate combination and dose. 1,2 Pregnant women, shift workers, heavy drinkers (alcohol intake >80 g/ day), heavy smokers (>20 cigarettes/ day), and heavy exercisers were excluded, as were individuals with either type 1 diabetes, or secondary arterial hypertension and cardiovascular disorders, including concomitant unstable angina pectoris, heart failure, stroke, life-threatening arrhythmia, atrial fibrillation, nephropathy, grade III-IV retinopathy, or prior (within the last year) myocardial infarction or coronary revascularization.
Study design. With these inclusion/exclusion criteria, we identified 1,830 subjects, and 1,794 provided all required information including a valid 48-h ABPM profile (see below). Among these, 1,306 subjects (724 men and 582 women), 61.6 ± 11.3 years of age were considered as patients with true resistant hypertension because they either showed uncontrolled BP or they were treated with ≥4 drugs. Uncontrolled BP based on ABPM required an awake BP mean of ≥135/85 mm Hg for SBP/DBP, or an asleep BP mean ≥120/70 mm Hg. 1 This was a cross-sectional study comparing groups of subjects with resistant hypertension divided as a function of the time of day of antihypertensive treatment: either ingesting all medication on awakening (53% of the sample in this study), or ingesting ≥1 BP-lowering medication at bedtime. All subjects gave written informed consent. The demographic and analytical characteristics of the subjects with true resistant hypertension are described in Table 1 . Blood samples were obtained in the clinic from the antecubital vein between 8 and 9 am after nocturnal fasting the same week when 48-h ABPM was initiated. The subjects collected their urine during the first 24 h of ABPM. Blood and urine were analyzed for the variables described in Table 1 using routine automatic techniques at the hospital laboratory. Just before starting ABPM, six clinic BP measurements were obtained after the subjects had rested in a seated position for at least 10 min, using a validated automatic oscillometric device (HEM-705IT; Omron Healthcare, Vernon Hills, IL). Diagnosis of obstructive sleep apnea (apnea/hypopnea index ≥10) was corroborated by overnight polysomnography at the clinic in subjects suspected of having the condition because of daytime sleepiness, loud snoring, nocturnal choking, and awakenings, interrupted breathing events, or all four of these as reported by the patient or a bedmate. Therapy with continuous positive airway pressure was applied in patients with apnea/hypopnea index ≥30.
ABPM assessment. The SBP, DBP, and heart rate of each participant were automatically measured every 20 min from 7 am to 11 pm and every 30 min during the night for 48 consecutive hours with a properly calibrated Spacelabs 90207 device (Spacelabs, Issaquah, WA). Participants were instructed to go about their usual activities with minimal restrictions but to follow a similar schedule during the 2 days of ABPM and to avoid daytime napping.
BP series were not considered valid for analysis if >30% of the measurements were missing, if data were missing for an interval of >2 h, if data were obtained while patients had an irregular rest-activity schedule during the 2 days of monitoring, or if the night-time sleep period was <6 h or >12 h during ABPM. Protocol-correct data series were collected from 1,794 subjects (1,306 with true resistant hypertension) and therefore included in this study. Profiles of 36 additional subjects fulfilling the inclusion criteria were eliminated due to inadequate BP sampling.
Actigraphy. All participants wore an actigraph (MiniMotionlogger; Ambulatory Monitoring, Ardsley, NY) on the dominant wrist to monitor physical activity every minute during ABPM. This compact (about half the size of a wristwatch) device works as an accelerometer. We synchronized the internal clocks of the actigraph and the ABPM device through their respective interfaces using the same computer. The actigraphy data were used to corroborate absence of daytime napping, and to determine the beginning and the end of daytime activity and nocturnal sleep so the awake and asleep BP means for each patient could be determined with accuracy.
Statistical methods. Each individual's clock hour BP and heart rate values were first referenced to hours after awakening from nocturnal sleep, based on data obtained by wrist actigraphy. This transformation avoided the introduction of bias due to differences among subjects in their sleep/activity routine. 9 To correct for measurement errors and outliers, BP and heart rate were edited according to conventional criteria. 13 Thus, readings of SBP >250 or <70 mm Hg, DBP >150 or <40 mm Hg, and pulse pressure (PP, difference between SBP and DBP) >150 or <20 mm Hg were automatically discarded.
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Hourly BP means obtained for each group of subjects categorized according to the time of treatment (either all medications on awakening or ≥1 drug at bedtime) were compared by t-test corrected for multiple testing. In so doing, the level of significance was established at P ≤ 0.002, after dividing the usual level of 0.05 by the number of tests (24, one for each hourly mean) done on the same variable.
The awake/asleep BP ratio (an index of BP dipping), defined as the percent decrease in BP during the hours of nocturnal rest relative to the mean BP obtained during the hours of daytime activity, was calculated as follows: ((awake BP mean − sleep-time BP mean)/awake BP mean) × 100, using all the data sampled by ABPM for 48 consecutive hours. For comparative purposes, patients were defined as dipper if the awake/asleep SBP ratio was ≥10%, and as nondipper otherwise. The morning BP was calculated as the average BP during the first 2 h after wake-up time. The morning BP surge was calculated as the difference between the morning BP and the hourly average centered on the lowest night-time BP reading. 14 The ambulatory arterial stiffness index was calculated as 1 minus the regression slope of DBP on SBP from ABPM. 15 All these ABPM parameters were compared between the two treatment-time groups by t-test. The demographic and clinical characteristics in Table 1 were compared among groups by t-test (quantitative variables) or nonparametric χ 2 test. Because the albumin excretion does not follow a normal distribution, a log-transformation was applied before statistical testing. We also compared among groups the proportion of patients with clinic PP ≥65 mm Hg, as well as the proportion of patients with 24-h PP mean >53 mm Hg, as these two threshold values are considered abnormal and have been shown to predict adverse prognosis. 16, 17 results demographic characteristics and analytical parameters
The two groups of subjects with true resistant hypertension categorized as a function of the time of their antihypertensive treatment were comparable in terms of the number of ingested drugs ( Table 1) . The most frequent combinations included an angiotensin-II receptor blocker (71%) or angiotensinconverting enzyme inhibitors (25%) with a diuretic (hydrochlorothiazide), and a dihydropyridine calcium channel blocker (81%) or an α-blocker (58%; always doxazosin GITS) included in the treatment regimen. β-blockers were used by about 29% of the patients in either group. There were no significant differences in the frequency of use of any given type of antihypertensive medication among groups. Results from Table 1 reveal the lack of differences between treatment groups in the prevalence of type 2 diabetes, obstructive sleep apnea, metabolic syndrome (ATP-III revised definition 18 ), dyslipidemia, current smoking, obesity (body mass index ≥30 kg/m 2 ), and sedentary lifestyle (here defined as no regular physical activity at least 30 min/day for at least 2 days/week), as determined by questionnaire and personal interview with each participant.
The two treatment groups of subjects were also comparable in age, body mass index, and waist perimeter ( Table 1) .
Clinic BP measurements, including PP, were slightly but significantly lower in subjects ingesting medication at bedtime. The percentage of subjects with clinic PP ≥65 mm Hg was significantly lower in this latter group (P = 0.007). Results original contributions
also reveal significantly lower average values of glucose, total cholesterol, low-density lipoprotein-cholesterol, fibrinogen, globular sedimentation rate, and 24-h urinary albumin excretion in patients with true resistant hypertension treated with ≥1 drug at bedtime ( Table 1 ). The percentage of subjects with microalbuminuria (albumin >30 mg/24 h) was similar in both groups. Differences among groups in albumin excretion were significant even after exclusion of patients with proteinuria ( Table 1) .
aBPM characteristics
Among the subjects who were ingesting three antihypertensive drugs, 488 (27.2%) had controlled ambulatory BP according to the criteria mentioned above. 1 The percentage of controlled subjects was significantly higher (31.9%) among those ingesting ≥1 antihypertensive drug at bedtime, as compared to subjects treated with all drugs on awakening (23.1%; P < 0.001).
For the remaining 1,306 subjects with true resistant hypertension, Figure 1 shows the circadian pattern of (a) SBP and (b) DBP of both groups of participants categorized according to the time of treatment. Results reveal a reduction in BP during the middle of diurnal active hours, higher than the described postprandial valley documented at the same location in either normotensive subjects or untreated hypertensive patients. 9 Due to the absence of diurnal napping corroborated by wrist actigraphy, this reduction in BP seems to be related with shorter than 24-h BP-lowering effects of morning dosing with many antihypertensive drugs. 19 As compared to patients treated with all drugs on awakening, patients with true resistant hypertension who were ingesting ≥1 antihypertensive drug at bedtime showed a significantly lower 24-h BP mean by 4.1/1.5 mm Hg in SBP/DBP, respectively (Figure 1; Table 2 ). This difference between groups was more prominent in asleep BP mean (9.7/4.4 mm Hg, 
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Ambulatory BP in Resistant Hypertension P < 0.001). Accordingly, the awake/asleep SBP ratio was significantly higher by 5.8% (P < 0.001) and the prevalence of nondipping lower from 83 to 40% (P < 0.001) in patients receiving ≥1 drug at bedtime. The prevalence of nondipping was progressively increasing with added medication in single morning dose, from 79% in patients ingesting 3 drugs on awakening, to 82% in those ingesting 4 drugs on awakening, and to a highest 91% in those treated with ≥5 drugs on awakening. Differences in hourly BP averages among the two timedtreatment groups were statistically significant at all sleeptime hours as well as at the beginning of the active period (Figure 1) . Because there were more controlled subjects among those receiving treatment at bedtime, differences in BP among groups, depicted in Figure 1 for patients with true resistant hypertension, are even higher when results are based on data from all participants in this study. Despite these differences in BP, the circadian heart rate pattern was comparable between groups (Figure 2a) . Treatment at bedtime was also associated with a significantly lower ambulatory PP (Figure 2b) . Differences in PP between groups were more pronounced in the asleep PP mean ( Table 2) .
With regard to additional ABPM parameters that have been identified as potential predictors of cardiovascular risk, morning BP was significantly lower (P < 0.001) among subjects ingesting ≥1 drug at bedtime ( Table 2 ). The morning BP surge was higher in this group, mainly as a consequence of the enhanced effects of bedtime treatment in regulating night-time BP. The percentage of subjects with morning SBP surge ≥55 mm Hg (a threshold value previously reported to be associated with increased risk for stroke 14 ) was, however, very low in both groups. The cutoff value of the top decile for the morning SBP surge in the present study was 37.5 mm Hg. The percentage of subjects within this top decile was significantly higher among those ingesting all drugs on awakening (P = 0.018; Table 2 ). Finally, the ambulatory arterial stiffness index was also significantly lower (P < 0.001) in subjects ingesting medication at bedtime.
discussion
This cross-sectional study of a large sample of subjects with resistant hypertension evaluated by 48-h ABPM indicates, first, the percentage of participants with awake, asleep, and 24-h BP mean values below currently accepted diagnostic thresholds of hypertension 1 was significantly higher among subjects treated at bedtime, as compared to those ingesting all their prescribed BP-lowering medication upon awakening. In a recent prospective randomized trial, subjects with resistant hypertension who were ingesting three drugs on a single morning dose were randomized to one of two groups according to the modification in their treatment strategy: either changing one of the drugs, but keeping all three in single morning dose, or the same approach but administering the new drug at bedtime. The percentage of subjects with controlled ambulatory BP after a 3-month intervention increased by 37% among those scheduled to ingest one drug at bedtime, independently of the type of medication. 11 Results from the present study also reveal a high prevalence of a nondipper BP profile in subjects with true resistant hypertension (mainly those ingesting all medications on awakening). A high prevalence of nondipping was previously noted in another study on the 24-h pattern of ABPM in resistant hypertension. 7 No attention was paid in this trial, however, to the time of antihypertensive treatment. The authors reported a 69% prevalence of nondipping, close to the 64% prevalence found in our study for the total sample evaluated independently of treatment time ( Table 2) . A recent cross-sectional study on Spanish subjects concluded that nondipping was associated with increased number of BP-lowering medication, but not to the time of treatment. 10 In this study, however, The awake/asleep ratio, an index of BP dipping, is defined as the percent decline in BP during the hours of nocturnal rest relative to the mean BP obtained during the hours of daytime activity, and calculated as follows: ((awake BP mean − asleep BP mean)/awake BP mean) × 100. Morning BP is defined as the average BP during the first 2 h after wakeup time. The morning BP surge is calculated as the difference between the morning BP and the hourly average centered on the lowest BP reading during night-time sleep.
Values are shown as mean ± s.d. AASI, ambulatory arterial stiffness index; BP, blood pressure; DBP, diastolic blood pressure; nondipper, subjects with awake/asleep SBP ratio <10%, using data sampled by ambulatory BP monitoring for 48 consecutive hours; PP, pulse pressure; SBP, systolic blood pressure.
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time of treatment was not randomized, and the percentage of subjects ingesting medication at night was thus below 20% of the total sample. According to previous reports, 9 treatment at bedtime in the Spanish primary care setting is so far only considered as an option mainly for uncontrolled subjects treated with ≥3 drugs. Thus, results might be biased by comparing the prevalence of nondipping between all patients receiving morning treatment (including those ingesting just one or two drugs) and those who ingested any drug at bedtime, independently of the number of drugs in their treatment schedule. Indeed, the prevalence of nondipping in this latter group was below 54%, markedly lower than the reported prevalence of nondipping in all previous studies on resistant hypertension. 7, 11, 12 We also found a significantly lower BP during the hours of night-time sleep in subjects with resistant hypertension ingesting medication at bedtime (Figure 1) . The greater effect of this therapeutic approach on the asleep than the awake BP mean resulted in a significantly lower prevalence of nondipping from 83 to 40% ( Table 2 ). This may be clinically relevant because nondipping (although based on an arbitrary definition) has been related to an increase in end-organ injury and cardiovascular events, 20-23 also in subjects with resistant hypertension. 8 Overall, these studies indicate reduction of the expected >10% sleep-time decline in BP constitutes a significant risk factor of cardiovascular mortality that is independent of the 24-h BP mean, i.e., the presence or absence of an elevated BP above the threshold used to diagnose hypertension. Moreover, nighttime BP, particularly the asleep SBP mean, seems to be a better predictor of cardiovascular morbidity and mortality than daytime or 24-h BP mean values. 8, 20, 22, 24 A significantly higher asleep BP ( Table 2 ) characterizes subjects ingesting all treatment on awakening, thus suggesting a potentially increased cardiovascular risk. The potential reduction in cardiovascular risk associated with the normalization of the circadian BP pattern (i.e., by increasing the awake/asleep BP ratio) is, however, still a matter of debate.
Apart from the awake/asleep BP ratio, other specific features of the 24-h BP pattern have been assessed as potential sources of injury to target tissues and as triggers of cardiac and cerebrovascular events in hypertensive patients. For example, the level of BP immediately after waking (morning BP) and the rate of BP rise coincident with the commencement of diurnal activity have been hypothesized to be a trigger for the documented higher incidence of myocardial infarction and stroke 25, 26 at this time of the day. In the present study, the level of morning BP was significantly lower, but the morning BP surge slightly higher, among subjects ingesting medication at bedtime (Figure 1; Table 2 ). The prospective studies that investigated the prognostic significance of the morning BP surge show inconsistent results. A large morning BP surge was associated with a significantly lower risk of total cardiovascular events in the Syst-Eur study. 20 On the contrary, a morning BP surge within the top decile (there a value >55 mm Hg) was associated with a significantly higher risk of stroke in the Jichi Medical School ABPM study, 14 and of total cardiovascular events in the Bordeaux hypertensive cohort study. 27 In the Ohasama study, a large morning BP surge was not associated with the risk of total stroke events, but rather with a higher risk of cerebral hemorrhage. 28 In the present study, only 11 out of 1,306 subjects with true resistant hypertension showed a morning BP surge above the previously provided threshold of 55 mm Hg, whereas the actual cutoff value for the top decile was almost 20 mm Hg lower ( Table 2) , suggesting marked (ethnic and other) differences between the subjects of both studies.
On the other hand, increased PP, reflecting large artery stiffness, is an independent marker of cardiovascular risk, mainly for myocardial infarction, congestive heart failure, and cardiovascular deaths. 29 The predictive value of PP for adverse cardiovascular events increases with age and, in particular, in subjects >50 years of age, it appears to be superior to that of SBP or DBP. 30 In the present study, 84% of the participants were ≥50 years of age. Despite lack of differences in age between treatment groups, clinic and ambulatory PP were significantly higher in subjects ingesting all medications on awakening ( Figure 2 ; Table 2 ). Previous randomized chronotherapy clinical trials reviewed elsewhere 19 have consistently documented a significantly greater effect in reducing ambulatory PP (mainly night-time PP) of bedtime as compared to morning ingestion of several antihypertensive medications, including angiotensin-II receptor blocker (valsartan, telmisartan, and olmesartan), angiotensin-converting enzyme inhibitors (ramipril and spirapril), and calcium channel blockers (nifedipine and amlodipine). Moreover, the ambulatory arterial stiffness index, a potential subrogate marker of arterial stiffness and a valuable predictor of cardiovascular mortality, 15 was significantly lower in subjects ingesting ≥1 drug at bedtime ( Table 2) .
Subjects treated with ≥1 drug at bedtime were also characterized by lower values of plasma glucose. This result seems even more relevant taking into account that the prevalence of previously diagnosed type 2 diabetes was comparable in both groups (Table 1) . Additionally, total cholesterol and low-density lipoprotein-cholesterol were also lower in patients treated at bedtime. The prevalence of dyslipidemia and metabolic syndrome were slightly lower in this group, although differences did not reach statistical significance. Globular sedimentation rate, a marker of inflammation, and plasma fibrinogen, a significant parameter for assessing the risk of acute myocardial infarction and stroke, were also significantly lower in subjects ingesting medication at bedtime ( Table 1) . Prospective randomized chronotherapy trials have already documented a significant decrease, not only in fibrinogen but also in urinary albumin excretion, correlated with the decrease in the asleep BP mean and, mainly, with the increase in the awake/asleep BP ratio associated with bedtime antihypertensive treatment. 31 International guidelines recommend the use of long-acting, once-daily medications that provide 24-h efficacy; 1 they improve adherence to therapy and minimize BP variability, providing smoother and more consistent BP control. Most antihypertensive medications have been approved in Spain and elsewhere to be used once daily, without specification of original contributions Ambulatory BP in Resistant Hypertension ingestion time. Use of a medication with high homogeneous efficacy throughout the 24 h is unlikely to affect the circadian profile of BP and exemplify good treatment choices for dipper hypertensive patients. This therapeutic scheme, however, may not be appropriate for managing nondippers (highly prevalent among subjects with resistant hypertension) because it is important to avoid nocturnal hypertension. 20, 24 The available scientific evidence suggests nondipper hypertensives may benefit from an evening (as opposed to morning) dosing schedule of most BP-lowering medications to best reduce abnormally high sleep-time BP and to convert the disturbed nondipping 24-h BP profile to the normal dipper one, which is known to be associated with reduced cardiovascular risk. 19 In conclusion, results from this cross-sectional study on a large sample of subjects with resistant hypertension indicate time of treatment, in relation to the rest-activity cycle of each individual, represents a key factor for BP control and the modeling of the circadian BP pattern. Treatment at bedtime was associated with a significantly greater prevalence of subjects with controlled BP during both activity and resting spans. Among subjects with true resistant hypertension, those ingesting medication at bedtime also showed significantly lower night-time BP, morning BP, and ambulatory PP, as well as higher awake/asleep BP ratio and thus a reduced prevalence of a high-risk nondipper BP pattern. This timed-treatment group was also characterized by lower mean values of glucose, total cholesterol, low-density lipoprotein-cholesterol, fibrinogen, and urinary albumin excretion. In resistant hypertension, pharmacological therapy should take into account time of day of treatment, to improve BP control and to avoid the nondipper pattern associated with higher cardiovascular risk. Whether this normalization of the BP pattern could also decrease cardiovascular risk in subjects with resistant hypertension, beyond the expected reduction in risk derived from lowering BP mean values, is a hypothesis under current prospective investigation. 32 
